Mimedx (MDXG) Free Cash Flow Growth (5y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.56% |
| Dec 31, 2025 | 31.86% |
| Sep 30, 2025 | 49.74% |
| Jun 30, 2025 | 43.38% |
| Mar 31, 2025 | 18.84% |
| Dec 31, 2024 | 23.01% |
| Sep 30, 2024 | 49.97% |
| Jun 30, 2024 | 64.51% |
| Mar 31, 2024 | 18.17% |
| Dec 31, 2023 | 97.48% |
| Sep 30, 2023 | 59.06% |
| Jun 30, 2023 | -16.32% |
| Mar 31, 2023 | -21.60% |
| Dec 31, 2022 | -28.73% |
| Sep 30, 2022 | -46.54% |
| Jun 30, 2022 | -17.62% |
| Mar 31, 2022 | -24.35% |
| Dec 31, 2021 | -20.83% |
| Sep 30, 2021 | 34.81% |
| Jun 30, 2021 | -26.41% |
| Mar 31, 2021 | -23.63% |
| Dec 31, 2020 | -45.82% |
| Sep 30, 2020 | -24.02% |
| Jun 30, 2020 | -31.85% |
| Mar 31, 2020 | -46.04% |
| Dec 31, 2019 | -43.55% |
| Sep 30, 2019 | -18.85% |
| Jun 30, 2019 | 10.30% |
| Mar 31, 2019 | -57.43% |
| Dec 31, 2018 | -16.06% |
| Sep 30, 2018 | 11.75% |
| Jun 30, 2018 | 65.73% |
| Mar 31, 2018 | 39.45% |
| Dec 31, 2017 | 81.77% |
| Sep 30, 2017 | 73.27% |
| Jun 30, 2017 | 92.65% |
| Mar 31, 2017 | 59.28% |
| Dec 31, 2016 | 62.39% |
| Sep 30, 2016 | 27.53% |
| Jun 30, 2016 | 35.46% |
| Mar 31, 2016 | -9.44% |